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OBJECTIVEdPatients with diabetes have a high risk of end-stage renal disease (ESRD). We
examined whether prediction of this outcome, according to chronic kidney disease (CKD) stag-
ing by creatinine-based estimates of the glomerular filtration rate (eGFRcreat), is improved by
further staging with serum cystatin C–based estimates (eGFRcyst).
RESEARCHDESIGNANDMETHODSdPatients with diabetes in CKD stages 1–3 were
selected from three cohorts: two from Joslin Diabetes Center, one with type 1 diabetes (N = 364)
and one with type 2 diabetes (N = 402), and the third from the Finnish Diabetic Nephropathy
(FinnDiane) Study of type 1 (N = 399). Baseline serum concentrations of creatinine and cystatin C
were measured in all patients. Follow-up averaged 8–10 years and onsets of ESRD (n = 246) and
death unrelated to ESRD (n = 159) were ascertained.
RESULTSdAlthough CKD staging by eGFRcyst was concordant with that by eGFRcreat for
62% of Joslin patients and 73% of FinnDiane patients, those given a higher stage by eGFRcyst
than eGFRcreat had a significantly higher risk of ESRD than those with concordant staging in all
three cohorts (hazard ratio 2.3 [95%CI 1.8–3.1]). Similarly, patients at a lower stage by eGFRcyst
than by eGFRcreat had a lower risk than those with concordant staging (0.30 [0.13–0.68]).
Deaths unrelated to ESRD followed the same pattern, but differences were not as large.
CONCLUSIONSdIn patients with diabetes, CKD staging based on eGFRcyst significantly
improves ESRD risk stratification based on eGFRcreat. This conclusion can be generalized to
patients with type 1 and type 2 diabetes and to diabetic patients in the U.S. and Finland.
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Considerable effort has been devotedtoward developing an accurate esti-mate of the glomerular filtration rate
(eGFR) based on an easily assayed endog-
enous biomarker (1–3). The most widely
used method is based on serum creati-
nine and a formula developed in the
Modification of Diet in Renal Disease
(MDRD) Study and designated here as
eGFRmdrd (4). Recently, the Chronic Kid-
ney Disease (CKD)-Epidemiology Collabo-
ration (EPI) Group developed a second
formula that ismore accurate in the normal
range and designated here as eGFRcreat
(5). These two formulas are the foundation
for staging CKD and guiding clinical prac-
tice (6,7).
An alternative endogenous serum
biomarker, cystatin C, has been proposed
for estimating renal function. Cystatin C
is a 13-kDa protein that is freely filtered at
the glomerulus and almost completely
reabsorbed in proximal tubules and catab-
olized by epithelial cells. Its synthesis is
believed to be constant and independent of
muscle mass and diet (8). Stevens et al. (9)
developed an eGFR formula based on cys-
tatin C (eGFRcyst).
Evaluations of eGFRcyst and eGFR-
creat against a measurement standard,
iothalamate clearance, found no major
advantage of one over the other (10,11).
However, a more cogent standard for com-
paring eGFRcyst and eGFRcreat is their
ability to predict end-stage renal disease
(ESRD), the clinically important outcome
addressed in this study. A potentially com-
plicating factor is that cystatin C may carry
information about disease processes be-
yond its role in estimating GFR. In the el-
derly, for example, eGFRcyst predicts
death from cardiovascular disease (CVD)
more accurately than eGFRcreat (12). If
true, predictions could be biased because
the risk of death from CVD competes with
the risk of ESRD. Moreover, eGFRcyst im-
proves identification of nondiabetic sub-
jects in CKD stage 3 (based on eGFRcreat)
at risk for complications (13). Similar
studies have not been performed in pa-
tients with diabetes, a population of par-
ticular interest because of its high risk of
ESRD and death unrelated to ESRD. Thus,
in this report, we examine whether the
predicted risk of ESRD and the competing
risk of death based on eGFRcreat are re-
fined by determination of eGFRcyst. To
examine whether our findings could be
generalized to all patients with diabetes,
we studied groups that differed by nation-
ality and type of diabetes.
RESEARCH DESIGN AND
METHODSdWe used data from three
long-term follow-up studies of the risk of
ESRD: two previously published studies
of patients with type 1 diabetes (T1D) and
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proteinuria (14,15) and one study of pa-
tients with type 2 diabetes (T2D) (16).
From each study we included only patients
with CKD stages 1–3 as determined by se-
rum creatinine concentration and the CKD-
EPI formula (eGFRcreat). The protocols and
consent procedures for each study were ap-
proved by the relevant institutional review
board. Written informed consent was ob-
tained from each participating patient. A
brief description of each study follows.
Joslin cohorts
The Joslin Clinic is a large center for the
treatment of patients of all ages with di-
abetes, regardless of type. Patient care
includes control of diabetes and treatment
of the late complications. Most patients
come to the clinicwithin5yearsof diagnosis,
andmany remainwith the clinic for decades,
receiving integrated care from endocrinolo-
gists, nephrologists, and ophthalmologists.
About one-fourth of the 16,000 patients
under the care of the clinic have T1D.
Joslin T1D cohort. Between 1991 and
2004, we recruited 423 patients with T1D
and proteinuria for studies of the genetics
of diabetic nephropathy. Details of the
selection, examination, and follow-up of
this cohort were provided in a previous
publication (14). The analysis in this re-
port includes the 364 Caucasian patients
with CKD stage 1–3 at baseline. These
patients were monitored through 2008
for the occurrence of ESRD or death un-
related to ESRD.
Joslin T2D cohort. Between 1991 and
1995, we recruited 560 patients with T2D
(half with normoalbuminuria and half
with microalbuminuria or proteinuria)
for studies of the genetics of diabetic
nephropathy. Details of the selection,
examination, and follow-up of this cohort
were provided in a previous publication
(16). The analysis in this report includes
402 patients (93% Caucasian) with CKD
stage 1–3 at baseline for whom baseline
serum was available for biochemical ex-
amination. The cohort was monitored
through 2004 for the occurrence of
ESRD or death unrelated to ESRD.
Finnish Diabetic Nephropathy (FinnDiane)
T1D cohort. The cohort used in this
study is part of the ongoing nationwide,
multicenter FinnDiane Study. The pa-
tients included in the present analysis
had their baseline examination between
1995 and 2006. Those with proteinuria at
baseline were included in a study of the
risk of ESRD and death unrelated to
ESRD, the results of which were recently
reported (15). The analysis in this report
includes 399 Caucasian patients with
CKD stage 1–3 at baseline, for whombase-
line serum was available for biochemical
measurements. The cohort was monitored
through 2008 for the occurrence of ESRD
or death unrelated to ESRD.
Baseline characteristics
Enrollment examinations were per-
formed by trained recruiters in all studies
and included a structured interview about
medical history, blood pressure measure-
ments, and anthropometric measure-
ments. Blood and urine were collected
for biochemical studies. The data ob-
tained at the baseline examination were
supplemented with clinical data from
medical records (14–16). Baseline charac-
teristics are reported in Table 1.
Determination of serum creatinine
and cystatin C
In 2009 and 2010, creatinine and cystatin
C were assayed in stored baseline serum
samples from the three cohorts in the
Advanced Research and Diagnostic Labora-
tory at the University of Minnesota. Serum
creatinine was measured with the Roche
enzymatic assay (Prod. No. 11775685) on a
Roche/Hitache Mod P analyzer. The method
is calibrated to be traceable to an isotope
dilution mass spectrometry creatinine re-
ference method, and the calibration has
been verified by regularly measuring Na-
tional Institute of Standards and Technol-
ogy Standard Reference Material (NIST
SRM) No. 967. The GFR was estimated
from the serum concentration of creatinine
inmilligramsperdeciliterwith the eGFRcreat
formula (4) and the eGFRmdrd formula (4).
Serum cystatin C was measured with a
particle-enhanced immunonephelometric
assay using reagents from Siemens-Dade-
Behring on a BN ProSpec (Siemens Health-
care Diagnostics, Inc., Deerfield, IL). Serum
cystatin C assay was standardized by trace-
ability to higher-order primary reference
materials bymultiplying the values obtained
at the University of Minnesota Laboratory
by 1.12 (17). The GFR was then estimated
Table 1dBaseline characteristics of the three cohorts with diabetes
Cohort
Joslin T1D FinnDiane T1D Joslin T2D
n 364 399* 402
Male (%) 55 56 56
Caucasian (%) 100 100 94
Age at diabetes diagnosis (years) 13.3 6 8.3 11.5 6 8.0 42.5 6 9.1
Duration of diabetes (years) 24.9 6 8.4 29.1 6 8.3 13.3 6 7.9
Age at study enrollment (years) 38.3 6 8.8 40.1 6 10.7 55.8 6 9.9
BMI (kg/m2) 26.6 6 5.8 26.2 6 4.1 29.9 6 6.3
HbA1c (%) 9.1 6 1.7 9.0 6 1.6 8.5 6 1.7
Blood pressure (mmHg)
Systolic 132 6 18 142 6 19 135 6 18
Diastolic 78 6 10 82 6 10 79 6 10
Renoprotection
(ACE inhibitor/ARB) (%) 68 86 48
Albumin-to-creatinine ratio
(mg/g creatine) 774 (467, 1,387) NA 18 (8, 159)
24-h albumin excretion rate NA 382 (154, 959) NA
Serum creatinine (mg/dL) 1.16 6 0.45 1.20 6 0.42 0.83 6 0.27
Serum cystatin C (mg/L) 1.20 6 0.45 1.11 6 0.40 0.94 6 0.32
eGFRcreat (mL/min) 80 6 29 75 6 27 93 6 22
eGFRmdrd (mL/min) 74 6 30 68 6 26 94 6 30
eGFRcyst (mL/min) 71 6 32 76 6 32 89 6 33
Follow-up (person-years) 2,818 3,111 3,826
ESRD cases (n) 114 80 52
ESRD incident rate
(per 100 person-years) 4.0 2.6 1.4
Deaths unrelated to ESRD (n) 29 47 83
Mortality rate
(per 100 person-years) 1.0 1.5 2.2
Data are mean6 standard deviation or median (25th, 75th percentiles). ARB, angiotensin-receptor blocker;
NA, not applicable. *62 additional patients (including 16 who developed ESRD) were not used in the study
due to lack of sera for cystatin C determinations.
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from the serum concentration of standard-
ized cystatin C inmilligrams per liter using
the published eGFRcyst formula (9,17):
eGFRcyst = 127.7 3 (20.105 + 1.13 3
standardized cystine)21.17 3 age20.13 3
(0.91 if female) 3 (1.06 if black).
Determination of onset of ESRD
and death
Joslin cohorts. Patients enrolled were
monitored for the development of ESRD
or death by matching the study roster
against the medical records of the Joslin
Clinic, the United States Renal Data System
and the National Death Index. The onset of
ESRD was recorded as the date of the first
renal transplant (if it was preemptive kid-
ney transplant) or renal dialysis. The most
recent query took place in October 2010
and covered all incident cases of ESRD
between 1991 and the end of 2008. Living
subjects who were free of ESRD were
contacted during 2009. We were able to
ascertain the status (alive, ESRD, or death)
of 98% of the subjects through 2008.
FinnDiane cohort. Deaths, regardless of
cause, were identified by a search of the
Finnish National Death Registry and cen-
ter databases through 24 March 2009.
Cause of death was confirmed by death
certificate. ESRD was defined as a re-
quirement for dialysis or kidney trans-
plant and identified via a search of renal
registries and center databases and veri-
fied in medical records.
Statistical analyses
Characteristics of patients were summa-
rized by means and SDs or medians and
quartiles. Cumulative risks of ESRD were
calculated by actuarial methods. Covari-
ate effects on time-to-events were evalu-
ated in Cox regression models. Statistical
significance was set at a value of P, 0.05.
Analyses were conducted in SAS 9.2 soft-
ware (SAS Institute, Cary, NC).
RESULTSdDemographic clinical char-
acteristics of the two T1D cohorts were
similar, whereas those of the Joslin T2D
cohort were quite different. Age at diabetes
diagnosis was almost 30 years older; cur-
rent agewas older, and duration of diabetes
was shorter. Body weight and blood pres-
sure were higher, whereas urinary albumin
excretion (measured as the albumin-to-
creatinine ratio) was lower and eGFR was
higher. Moreover, the incidence rate of
ESRD was lower and the mortality rate due
to death unrelated toESRDwas higher than
in the T1D cohorts.
The three cohorts differed to some
degree in endogenous markers of renal
function. In the FinnDiane cohort, the con-
centration of creatinine was higher than in
the T1D Joslin cohort, whereas the concen-
tration of cystatin C was lower. As a conse-
quence of these differences,mean eGFRcreat
and eGFRmdrd were slightly lower in the
FinnDiane cohort (P = 0.02) than in the
Joslin cohort (P = 0.01) and mean eGFRcyst
was higher (P = 0.02). As expected, serum
concentrations of creatinine and cystatin C
in the Joslin T2D cohort were substantially
lower than in the T1D cohorts.
The distributions of patients in each
cohort according to CKD stage determined
by eGFRcreat and then partitioned by
eGFRcyst stage are reported in Table 2.
Concordant staging (numbers along the
main diagonal) predominated in all cohorts.
For example, in the Joslin T1D cohort,
those numbers (87 + 55 + 75) add to 217,
which is 60% of the cohort (n = 364). Con-
cordance was similar in the Joslin T2D
cohort (65%) and somewhat higher in
FinnDiane (73%). However, discordant
staging in the FinnDiane cohort differed
from that in the Joslin cohorts. It was sym-
metric in the FinnDiane cohort (eGFRcyst
stage higher for 16% and lower for 11%)
but very asymmetric in both Joslin cohorts
(eGFRcyst stage was higher than eGFR-
creat stage for 35% and lower for only
3%). This difference in the pattern of dis-
cordant classification in the Joslin and
FinnDiane cohorts was highly significant
(P , 0.0001).
We determined the ESRD incidence
rate in each cell of Table 2 to assess what
effect the partitioning of eGFRcreat stages
according to eGFRcyst stages had on the
risk of ESRD. The incidence rates are repor-
ted in Table 3. The partitioning produced
subgroups within each eGFRcreat stage
with a gradient of increasing ESRD risk;
moreover, the gradient was very similar
within each of the three cohorts. Thus, de-
spite the differences among the cohorts,
staging each eGFRcreat stage by eGFRcyst
stage, consistently, added information
about the risk of ESRD. By contrast, the
partitioning by eGFRcreat (along the col-
umns) of patients within an eGFRcyst stage
did not result in comparable gradients.
The incidence rates of ESRD during
follow-up that were reported in Table 3
can also be summarized by actuarial
methods as 10-year cumulative risks of
ESRD (Fig. 1). This representation of
ESRD risk is probably easier for clinicians
and patients to interpret when consider-
ing prognosis. Figure 1 shows the com-
bined results from a stratified modeling of
the Joslin and the FinnDiane T1D cohorts.
Relative to the subgroups where the
eGFRcyst and eGFRcreat stages agree
( bars), the 10-year risks were lower
( bars) if the eGFRcyst stage was lower
than the eGFRcreat stage, and higher
( bars) if the eGFRcyst stage was higher.
For T2D, the 10-year risks were also higher
if the eGFRcyst stage was higher than the
eGFRcreat stage, but if it was lower, the 10-
year risk could not be estimated because no
Table 2dDistribution of patients according to CKD stage defined by eGFRcreat and
partitioned by eGFRcyst stage
CKD stage by eGFRcyst
1 2 3 4
CKD stage by
eGFRcreat Total 290 mL/min 89–60 mL/min 59–30 mL/min 29–15 mL/min
Joslin T1D (mL/min)
1 (290) 151 87 (57.6) 64 (42.4) d d
2 (89–60) 110 5 (4.6) 55 (50.0) 50 (45.4) d
3 (59–30) 103 d 4 (3.9) 75 (72.8) 24 (23.3)
FinnDiane T1D
(mL/min)
1 (290) 125 98 (78.4) 27 (21.6) d d
2 (89–60) 135 24 (17.8) 89 (65.9) 22 (16.3) d
3 (59–30) 139 d 20 (14.4) 105 (76.5) 14 (10.1)
Joslin T2D (mL/min)
1 (290) 260 175 (67.3) 85 (32.7) d d
2 (89–60) 102 8 (7.8) 60 (58.8) 34 (33.3) d
3 (59–30) 40 d 5 (12.5) 26 (65.0) 9 (22.5)
Data are n (%) unless otherwise indicated.
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ESRD occurred among the few patients
there (datanot shown).Theanalyses inTables
2 and 3 were repeated using CKD stages
based on eGFRmdrd and the pattern of
ESRD risk was the same (Supplementary
Tables 1 and 2).
We tested the statistical significance
of differences presented in Table 3 using
a Cox proportional hazard model of time
to ESRD with adjustment for cohort dif-
ferences in urinary albumin excretion
and ACE inhibitor/angiotensin receptor
blocker use. Because the results within
each cohort were similar (Table 4), we
tested for significant heterogeneity of the
hazard ratios (HRs) across cohorts in a
joint model and found none; therefore,
the cohorts were combined for the final
analysis. For patients with concordant
staging by both eGFRcyst and eGFRcreat,
the summary HR for a one-step increase
in CKD stage was linear (3.3 [95% CI
2.7–4.0]). For patients with discordant
staging, the risk of ESRD for patients
with an eGFRcyst stage higher than their
eGFRcreat stage was significantly higher
than for those with concordant stages
(summary 2.3 [1.8–3.1]). Similarly, the
risk for patients with an eGFRcyst stage
lower than their eGFRcreatwas significantly
lower than that for those with concordant
stages (summary 0.30 [0.13–0.68]).
Altogether, only 159 deaths were un-
related to ESRD in the three cohorts, and
cardiovascular deaths accounted for
approximately two-thirds (Supplemen-
tary Table 1). We analyzed the mortality
rate in the same way as the incidence rates
of ESRD. The patterns of findings were
similar to those for ESRD, but the effect of
partitioning of eGFRcreat stages according
to eGFRcyst had a smaller effect on themor-
tality rates (Supplementary Tables 1 and 2).
The number of CVDdeathswas too small to
perform a separate analysis for such deaths.
CONCLUSIONSdPatients with dia-
betes have a very high risk of developing
ESRD as well as a high risk of dying
without developing ESRD. In this report,
we show for the first time that, for young
or middle-aged diabetic patients in CKD
stages 1–3 (based on routinemeasurements
of serum creatinine), a secondary assess-
ment of renal function based on serum cys-
tatin C significantly improves ESRD risk
stratification. This finding applies to Cauca-
sian patients with T1D and T2D in Boston
as in Finland and is true regardless of
whether the initial CKD stage is based on
the CKD-EPI or MDRD Study formulas.
CKD staging by both eGFRcreat and
eGFRcyst resulted in significant dis-
crepancies in approximately 25–35%
of patients. In the Joslin cohorts, the
predominant discordance was a higher
CKD stage by eGFRcyst than by eGFR-
creat. This is consistent with the evidence
that creatinine-based formulas underesti-
mate GFR in the normal range. Therefore,
it is the symmetric pattern of discordant
staging in the FinnDiane cohort that is un-
expected. Although the reason for this dif-
ference is unclear, we hypothesize that the
modestly higher serum creatinine in the
FinnDiane cohort was responsible. Fac-
tors other than GFR are known to influ-
ence serum creatinine, so population
differences most likely exist. They may
be due to differences in muscle mass or
diet and do not necessarily imply popula-
tion differences in kidney function. The
MDRD and CKD-EPI formulas were cali-
brated in Caucasian Americans. Estimates
based on a population with a different dis-
tribution of serum creatinine concentra-
tions, such as the FinnDiane cohort, will
be biased. If the higher creatinine in Finn-
Diane is due to something other than GFR
(as seems most likely), the CKD-EPI for-
mula underestimates their GFR and over-
estimates their CKD stage. This would
counter the tendency of eGFRcreat to un-
derestimate renal function and result in
the symmetric pattern of discordance in
the FinnDiane cohort.
Although the difference between the
distributions of serum creatinine concen-
trations in the Joslin andFinnDiane cohorts
raises concerns about the applicability of
the MDRD and CKD-EPI formulas across
diverse populations, the significantly im-
proved ESRD risk stratification provided
by a secondary assessment of renal function
based on serum cystatin C is robust against
these population differences. The partition-
ing of each eGFRcreat stage by eGFRcyst
stage distinguishes a significant gradient of
risk, with the risk increasing as eGFRcyst
stage increases. Interestingly, although the
pattern of discordant CKD stages depends
on whether the eGFRcreat (CKD-EPI) or
eGFRmdrd (MDRD) formula is used, the
pattern of a risk gradient with eGFRcyst
stage within each eGFRmdrd stage persists
(data not shown).
Should measurement of serum cysta-
tin C replace measurement of serum
creatinine in clinical settings or supple-
ment it in selected patients is a question
that arises. Several considerations influ-
ence the answer. First, one must take into
account that patients with diabetes have a
much higher risk of ESRD than the
general population and may require spe-
cial consideration. Second, although CKD
staging based on the serum creatinine
concentration and the MDRD or CKD-
EPI formula is inexpensive and already in
routine clinical use, secondary CKD stag-
ing based on serum cystatin C concentra-
tion of patients with normal or nearly
normal GFR improves stratification of
ESRD risk and limits the extra expense
to the subset of patients who can benefit
most. Whether this extra expense is jus-
tified depends on the cumulative risk of
ESRD (as illustrated in Fig. 1) and the
value of improved detection of patients
at high risk of ESRD. The latter depends
on the availability of effective inter-
ventions to prevent this outcome. The
Table 3dIncidence rate of ESRD in each cohort according to CKD stage defined by
eGFRcreat and partitioned by CKD stage defined by eGFRcyst
Rates per 100 person-years CKD stage by eGFRcyst
1 2 3 4
CKD stage by eGFRcreat 290 mL/min 89–60 mL/min 59–30 mL/min 29–15 mL/min
1 (290 mL/min)
Joslin T1D 1.5 2.4 d d
FinnDiane T1D 0.8 1.9 d d
Joslin T2D 0.1 1.0 d d
2 (89–60 mL/min)
Joslin T1D 3.3 1.7 4.3 d
FinnDiane T1D 0.5 1.7 2.2 d
Joslin T2D 0.0 1.5 5.3 d
3 (59–30 mL/min)
Joslin T1D d 2.9 9.9 25.3
FinnDiane T1D d 1.3 5.1 16.6
Joslin T2D d 0.0 9.4 13.5
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question deserves a formal cost-benefit
analysis, which is beyond the scope of
this report.
It is unclear that we can attribute the
ability of eGFRcyst to refine a prediction
of ESRD based on eGFRcreat simply to an
improved estimate of renal function and,
hence, a more accurate determination of
how much renal function must be lost to
reach ESRD. Only a marginal difference
between eGFRcreat and eGFRcyst has
been found in cross-sectional compari-
sons of them with a direct measurement
of GFR (iothalamate clearance) in nondia-
betic individuals (9–11). Another possibil-
ity is that serum cystatin C concentration
carries additional information about the
risk of other adverse outcomes. In the el-
derly general population, for example, the
serum concentration of cystatin C is a more
accurate predictor of death due to CVD
than serum creatinine (12). Possibly, vari-
ation in serum cystatin C reflects a mecha-
nism or risk factor involved in CVD that
is unrelated to renal function (18). The
Multi-Ethnic Study of Atherosclerosis
(MESA) and Cardiovascular Health Study
(CHS) demonstrated that for patients with
CKD stages$3 according to the creatinine-
based CKD-EPI equation, an adverse prog-
nosis was limited to the subset of patients
who had CKD stages $3 according to
eGFRcyst (13). The adverse outcomes in-
cluded death, cardiovascular event, heart
failure, and kidney failure. In a recent anal-
ysis of the Reasons for Geographic and Ra-
cial Differences in Stroke (REGARDS) study
of middle-aged individuals, adding cystatin
C to measures of creatinine and urinary al-
bumin excretion improved the predictive ac-
curacy for all-causemortality andESRD(19).
There is general agreement between
our results and those obtained in these
other studies, namely, that measurement
of serum cystatin C has value in assessing
risk of ESRD and death. The studies in
nondiabetic patients with CKD $3 (by
eGFRcreat) showed that eGFRcyst is a
predictor of ESRD and death. Our study
in patients with diabetes showed that dis-
cordant CKD staging by eGFRcreat and
eGFRcyst added particularly to the pre-
diction of ESRD risk, the principal risk
for this population. Thus, its utility is
not diminished by the fact that the rela-
tionship of serum cystatin C with mortal-
ity risk in diabetes, so well documented in
nondiabetic subjects (12,13,19), is only
marginally confirmed in our diabetic co-
horts. In summary, the risk of ESRD in-
creases with each stage of CKD, but
partitioning of each eGFRcreat stage by
eGFRcyst stage distinguishes a signifi-
cant gradient of risk, with the risk
Figure 1dTen-year cumulative risks of ESRD in patients with T1D were calculated by actuarial methods according to CKD stages determined
jointly by eGFRcrea and eGFRcyst. The pattern of differences was similar in the Joslin and FinnDiane cohorts of T1D, so the cohorts were pooled as
a single cohort. The percentages on the boxes are 10-year cumulative risks of ESRD. : Concordant CKDcyst and CKDcrea stages. : CKDcyst stage
is higher (eGFR is lower) than the CKDcrea stage. : CKDcyst stage is lower (eGFR is higher) than the CKDcrea stage.
Table 4dAnalysis of time to onset of ESRD in each cohort according to CKD stage
defined by eGFRcreat and partitioned by eGFRcyst stage
Cohort
CKD stages Joslin T1D FinnDiane T1D Joslin T2D
eGFRcyst higher than eGFRcreat stage* 2.2 (1.5–3.9) 2.2 (1.3–3.8) 3.2 (1.8–5.9)
Stages the same 1.0 (ref) 1.0 (ref) 1.0 (ref)
eGFRcyst lower than eGFRcreat stage† 0.4 (0.1–1.3) 0.3 (0.1–0.9) Indeterminate
Data are HR (95% CI) unless otherwise indicated. Adjusted for CKD stage and albumin-to-creatinine ratio
and albumin excretion rate. *P, 0.001 for Joslin, P = 0.0025 for FinnDiane. †P = 0.1 for Joslin T1D, P = 0.03
for FinnDiane.
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increasing as eGFRcyst stage increases.
The information gained from discordant
CKD staging can be important clinically
for advising patients about their risk of
ESRD or to tailor interventions to their
level of risk. This finding applies to Cauca-
sian patients with T1D and T2D in Boston
as in Finland and is true regardless of
whether the initial CKD stage is based on
the CKD-EPI or MDRD Study formulas.
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